CV-MG01

BIOLOGICAL2 trials

Sponsors

CuraVac

Conditions

Myasthenia GravisMyasthenia Gravis, Generalized

Phase 1

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis

CompletedNCT02609022

CuraVacMyasthenia Gravis

Start: 2016-03-31End: 2018-09-30Updated: 2019-01-28

Phase 2

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

WithdrawnNCT03165435

CuraVacMyasthenia Gravis, Generalized

Start: 2018-07-31End: 2019-12-31Updated: 2018-05-30